Exp Mol Med.  2013 Sep;45(9):e40.

The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis

  • 1Department of Biological Science, Sungkyunkwan University, Suwon, Korea. yoesik@skku.edu
  • 2Mitochondria Hub Regulation Center, College of Medicine, Dong-A University, Busan, Korea.
  • 3Genomic Informatics Center, Hankyong National University, Anseong, Korea.
  • 4Department of Biochemistry and Molecular Biology, College of Medicine, Yeungnam University, Daegu, Korea.
  • 5Institute for Medical Sciences, Ajou University School of Medicine, Suwon, Korea.
  • 6Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.


In this study, we examined the therapeutic effects of an immune-stimulating peptide, WKYMVm, in ulcerative colitis. The administration of WKYMVm to dextran sodium sulfate (DSS)-treated mice reversed decreases in body weight, bleeding score and stool score in addition to reversing DSS-induced mucosa destruction and shortened colon. The WKYMVm-induced therapeutic effect against ulcerative colitis was strongly inhibited by a formyl peptide receptor (FPR) 2 antagonist, WRWWWW, indicating the crucial role of FPR2 in this effect. Mechanistically, WKYMVm effectively decreases intestinal permeability by stimulating colon epithelial cell proliferation. WKYMVm also strongly decreases interleukin-23 and transforming growth factor-beta production in the colon of DSS-treated mice. We suggest that the potent immune-modulating peptide WKYMVm and its receptor FPR2 may be useful in the development of efficient therapeutic agents against chronic intestinal inflammatory diseases.


therapeutics; ulcerative colitis; WKYMVm
Full Text Links
  • EMM
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr